Stay updated on Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page.

Latest updates to the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page
- Check3 days agoChange DetectedThe page footer revision was updated from v3.5.2 to v3.5.3, indicating a minor site/version update without changing the study information presented.SummaryDifference0.1%

- Check11 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check40 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0. No visible changes to the study details or page functionality.SummaryDifference0.1%

- Check47 days agoChange DetectedRevision updated: v3.4.2 removed; v3.4.3 added.SummaryDifference0.1%

- Check75 days agoChange DetectedAdded site revision tag Revision: v3.4.2 and removed an operating-status notice (lapse in government funding) along with Revision: v3.4.1. The core study details, eligibility criteria, and trial information remain unchanged.SummaryDifference0.5%

- Check82 days agoChange DetectedA site-wide status notice regarding government funding and NIH operating status was added, and the page version updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

Stay in the know with updates to Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page.